Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Omeros Corp (OMER)
NASDAQ:OMER
Holding OMER?
Track your performance easily
OMER Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.92 - $5.68
Previous Close$4
Volume240.30K
Average Volume (3M)336.61K
Market Cap
$231.79M
Enterprise Value$264.27M
Total Cash (Recent Filing)$158.91M
Total Debt (Recent Filing)$191.39M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Nov 06, 2024EPS Estimate
-$0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.35
Shares Outstanding57,946,859
10 Day Avg. Volume254,826
30 Day Avg. Volume336,606
Standard Deviation0.26
R-Squared0.08
Alpha-0.00883
Financial Highlights & Ratios
Price to Book (P/B)-1.86
Price to Sales (P/S)196.86
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue175.01
Enterprise Value/Gross Profit176.18
Enterprise Value/Ebitda-2.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Omeros News
Bulls Say, Bears Say
Bulls Say
Debt ManagementThe transactions allow OMER to extend the maturity of 55% of its outstanding debt from 2026 to 2028 without equity dilution.
Public PresentationsInitial data from the PNH studies was presented at the recent EHA meeting and is expected to be part of a presentation at ASH in December.
Research And DevelopmentOMER's current pipeline focus has now shifted to OMS906, which is under evaluation in three open-label phase 2 studies in PNH and C3G.
Bears Say
Financial PerformanceAnalysts remain skeptical whether OMER can address the issues highlighted in the 2021 CRL, and put the product candidate on a potential path to FDA approval.
Pipeline And ValuationAnalysts maintain a Hold rating due to the early-stage nature of OMER's pipeline and the lack of near-term value drivers.
Regulatory ApprovalThere was no update on timelines for a resubmission of narsoplimab for HSCT-TMA.
---
Ownership Overview
6.21% Insiders
9.22% Mutual Funds
19.57% Other Institutional Investors
64.99% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OMER FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest stock price was $0.92 and its highest was $5.68 in the past 12 months.
What is Omeros Corp’s market cap?
Currently, no data Available
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were Omeros Corp’s earnings last quarter?
Omeros Corp released its earnings results on Aug 07, 2024. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.138 by $0.168.
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Overvalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is -$0.77.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 57,946,857 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Omeros Corp reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.138. Following the earnings report the stock price went down -5.783%.
Which hedge fund is a major shareholder of Omeros Corp?
Among the largest hedge funds holding Omeros Corp’s share is Sheaff Brock Investment Advisors LLC. It holds Omeros Corp’s shares valued at N/A.
---
Omeros Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
OMER Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 60.1K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-32.44%
Trailing 12-Months
Company Description
Omeros Corp
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
---
OMER Earnings Call
Q2 2024
0:00 / 0:00
---
OMER Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering OMER
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+56.39%
reiterated a buy rating 5 months ago
Copying Stephen Brozak's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +56.39% per trade.
---